Who Makes Wegovy, Why Does One Company Control the Supply, and What Happens When They Can't Keep Up?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy is manufactured exclusively by Novo Nordisk A/S, a Danish pharmaceutical company founded in 1923 that controls roughly 50% of the global insulin market and now dominates GLP-1 weight-loss medications
• The same active ingredient (semaglutide) appears in three Novo Nordisk products with different FDA approvals: Ozempic (diabetes, 2017), Wegovy (obesity, 2021), and Rybelsus (oral diabetes, 2019)
• Wegovy has been on the FDA drug shortage list intermittently since launch, with the most severe shortages occurring in 2022 and Q4 2023, driven by manufacturing capacity constraints at Novo Nordisk's fill-finish facilities in Denmark and North Carolina
• During FDA-recognized shortages, U.S. compounding pharmacies are legally permitted to produce semaglutide under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, creating a parallel supply chain that serves an estimated 300,000+ patients as of April 2026

Direct answer (40-60 words)

Wegovy is manufactured by Novo Nordisk A/S, a Danish pharmaceutical company headquartered in Bagsværd, Denmark. Novo Nordisk developed semaglutide, received FDA approval for Wegovy (semaglutide 2.4 mg for chronic weight management) in June 2021, and maintains exclusive patent protection through 2032. No other company is authorized to manufacture or sell branded Wegovy.

Table of contents

1. The manufacturer: Novo Nordisk's 100-year evolution from insulin to GLP-1 dominance
2. How Novo Nordisk developed semaglutide and why it took 13 years
3. The three versions of semaglutide and why Novo Nordisk sells the same molecule under different names
4. Where Wegovy is actually made: the manufacturing facilities and supply chain
5. Why one company controls the entire supply and what that means for patients
6. The shortage pattern: why Wegovy has been unavailable more often than available since launch
7. What most articles get wrong about "who makes Wegovy" when shortages happen
8. The compounded semaglutide alternative and how it's legally distinct from counterfeit drugs
9. Patent expiration timeline and when generic competition arrives
10. The Eli Lilly factor: why Mounjaro's manufacturer is the only real competitive threat
11. When you should care who makes your semaglutide and when it doesn't matter
12. FAQ

The manufacturer: Novo Nordisk's 100-year evolution from insulin to GLP-1 dominance

Novo Nordisk A/S is a publicly traded pharmaceutical company (NYSE: NVO, Copenhagen: NOVO B) founded in 1923 by August Krogh, a Danish Nobel Prize-winning physiologist, and his wife Marie Krogh, a physician treating diabetic patients. The company's original mission was to produce insulin for diabetes treatment after the discovery of insulin in 1921.

By 2026, Novo Nordisk employs roughly 63,000 people globally and generates approximately $35 billion in annual revenue. The company controls an estimated 32% of the global diabetes care market and 50% of the insulin market specifically (IQVIA World Review 2025).

The company's GLP-1 portfolio now represents the majority of revenue growth:

Product	Active ingredient	FDA approval year	2025 revenue (estimated)
Ozempic	Semaglutide 0.5-2 mg injectable	2017	$14.2 billion
Wegovy	Semaglutide 2.4 mg injectable	2021	$6.8 billion
Rybelsus	Semaglutide 7-14 mg oral	2019	$2.1 billion
Victoza	Liraglutide injectable	2010	$3.4 billion (declining)
Saxenda	Liraglutide 3 mg injectable	2014	$1.2 billion (declining)

Semaglutide products (Ozempic, Wegovy, Rybelsus) accounted for roughly $23 billion in 2025 revenue, making semaglutide the single most valuable pharmaceutical molecule by revenue in Novo Nordisk's history.

The company's headquarters remain in Bagsværd, Denmark, a suburb north of Copenhagen. Manufacturing occurs at facilities in Denmark, France, Brazil, China, and the United States (Clayton, North Carolina). Research and development operations are concentrated in Denmark, the U.S., the U.K., and China.

How Novo Nordisk developed semaglutide and why it took 13 years

Semaglutide's development began in 2003 as part of Novo Nordisk's long-acting GLP-1 analog program. The company had already developed liraglutide (approved 2010), a once-daily GLP-1 receptor agonist. Semaglutide was designed to be a once-weekly version with structural modifications to extend half-life.

The key innovation was adding a C18 fatty acid side chain to the GLP-1 peptide backbone, which allows the molecule to bind to albumin in the bloodstream. This albumin binding extends the elimination half-life from 2 to 3 hours (native GLP-1) to approximately 165 hours (one week), enabling once-weekly dosing.

The development timeline:

• 2003-2008: Preclinical development and analog screening
• 2008: First-in-human Phase 1 trial (Kapitza et al., Diabetes Obesity and Metabolism 2015)
• 2012-2016: Phase 2 and Phase 3 SUSTAIN trials for diabetes indication
• 2017: FDA approval for Ozempic (diabetes)
• 2017-2021: STEP trials for obesity indication
• 2021: FDA approval for Wegovy (obesity)

The total development cost from discovery to Wegovy approval is estimated at $1.8 to $2.3 billion, based on Novo Nordisk's disclosed R&D spending during the semaglutide program years (Novo Nordisk Annual Reports 2010-2021).

The 13-year timeline reflects the complexity of demonstrating cardiovascular safety (required for diabetes drugs post-2008 FDA guidance), conducting large-scale obesity trials (the STEP program enrolled over 4,500 patients), and navigating regulatory requirements across multiple indications.

The three versions of semaglutide and why Novo Nordisk sells the same molecule under different names

Novo Nordisk markets the same active pharmaceutical ingredient, semaglutide, under three brand names with different FDA-approved indications and dosing:

Ozempic (approved June 2017)

• Indication: Type 2 diabetes
• Doses: 0.25 mg, 0.5 mg, 1 mg, 2 mg once weekly
• Delivery: Pre-filled multi-dose pen
• FDA approval based on: SUSTAIN 1-10 trials (Sorli et al., Diabetes Care 2017; Marso et al., NEJM 2016)

Wegovy (approved June 2021)

• Indication: Chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidity
• Doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg once weekly (titration schedule)
• Delivery: Pre-filled single-dose pen
• FDA approval based on: STEP 1-4 trials (Wilding et al., NEJM 2021; Davies et al., Lancet 2021)

Rybelsus (approved September 2019)

• Indication: Type 2 diabetes
• Doses: 3 mg, 7 mg, 14 mg once daily oral tablet
• Delivery: Oral tablet with absorption enhancer (SNAC)
• FDA approval based on: PIONEER 1-8 trials (Aroda et al., Lancet 2019)

The reason for separate brand names is regulatory and commercial. The FDA approves drugs for specific indications. Ozempic's clinical trial program demonstrated glucose control and cardiovascular benefit in diabetic patients. Wegovy's STEP trials demonstrated weight loss in non-diabetic obese patients. Legally, these are distinct approved uses.

Commercially, separate branding allows differential pricing. Wegovy's list price is approximately $1,349 per month. Ozempic's list price is approximately $969 per month for the 2 mg dose (the same dose as Wegovy's maintenance dose). Insurance coverage differs: diabetes drugs are more widely covered than obesity drugs, creating pricing use.

The practice is common in pharmaceuticals. The same strategy applies to Eli Lilly's tirzepatide (Mounjaro for diabetes, Zepbound for obesity) and many other molecules with multiple indications.

Where Wegovy is actually made: the manufacturing facilities and supply chain

Wegovy is manufactured at Novo Nordisk facilities in two primary locations:

Kalundborg, Denmark (API production)

• Active pharmaceutical ingredient (semaglutide peptide) synthesis
• Fermentation and purification
• Largest biotech production facility in Denmark
• Capacity expansion completed in 2024 added 30% additional API production capability (Novo Nordisk press release, March 2024)

Hillerød, Denmark, and Clayton, North Carolina, U.S. (fill-finish)

• Pre-filled pen assembly
• Sterile filling of semaglutide solution into injection devices
• Quality control and packaging
• The Clayton facility opened in 2019 and underwent a $2 billion expansion completed in Q1 2025 specifically to increase Wegovy and Ozempic production (North Carolina Department of Commerce announcement, January 2025)

The supply chain bottleneck has consistently been fill-finish capacity, not API production. Novo Nordisk disclosed in Q2 2023 earnings calls that the company could produce sufficient semaglutide peptide to meet demand but lacked the sterile filling lines to convert API into finished pens at the required volume.

The pre-filled pen design is more complex to manufacture than vial-and-syringe formats. Each pen contains a multi-component injection mechanism, a glass cartridge, and requires sterile assembly under cleanroom conditions. The single-dose Wegovy pens are particularly manufacturing-intensive compared to the multi-dose Ozempic pens.

Novo Nordisk does not contract manufacturing to third parties for semaglutide products. All production occurs in-house at company-owned facilities. This vertical integration provides quality control but limits flexibility to scale rapidly during demand surges.

Why one company controls the entire supply and what that means for patients

Novo Nordisk's monopoly on Wegovy stems from three factors:

1. Patent protection. Novo Nordisk holds composition-of-matter patents on semaglutide (U.S. Patent 7,235,627 and related patents) that extend through 2032. No other company can legally manufacture or sell semaglutide in the U.S. without licensing from Novo Nordisk. The company has not licensed semaglutide to any competitors.

2. Regulatory exclusivity. Even if patents expired today, Wegovy holds 5 years of new chemical entity exclusivity from its 2021 FDA approval, preventing generic applications until 2026. Ozempic's exclusivity expired in 2022, but the composition patents remain in force.

3. Manufacturing complexity. Semaglutide is a modified peptide requiring recombinant production, not a small-molecule drug that can be synthesized in standard chemical reactors. The manufacturing process is proprietary, and replicating it requires significant capital investment and technical expertise.

The practical consequence: if Novo Nordisk cannot produce enough Wegovy, patients have no alternative branded source. The only options are:

• Wait for supply to resume
• Switch to Ozempic off-label (if available and if insurance covers it)
• Use compounded semaglutide from a 503A or 503B pharmacy during FDA-recognized shortages
• Switch to a different medication class entirely

This single-source dependency creates supply fragility. A manufacturing disruption, quality control issue, or demand surge immediately translates to patient access problems. The 2022-2023 Wegovy shortage illustrated this: Novo Nordisk voluntarily paused new patient starts in mid-2022 to preserve supply for existing patients, leaving tens of thousands unable to initiate treatment.

For comparison, the insulin market has multiple manufacturers (Novo Nordisk, Eli Lilly, Sanofi) producing competing products, which provides supply redundancy. The GLP-1 obesity market in 2026 has only two manufacturers: Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide). If both face shortages simultaneously, there is no backup.

The shortage pattern: why Wegovy has been unavailable more often than available since launch

Wegovy appeared on the FDA Drug Shortages Database on March 31, 2022, and has been listed intermittently since. The shortage timeline:

Period	Shortage status	Doses affected	Reason (per FDA/Novo Nordisk)
June 2021 - Feb 2022	Available	None	Initial launch supply adequate
March 2022 - Sept 2023	Severe shortage	All doses	Demand exceeded manufacturing capacity
Oct 2023 - Dec 2023	Resolved	None	Capacity expansion online
Jan 2024 - March 2024	Intermittent	Starter doses (0.25, 0.5 mg)	Allocation prioritizing maintenance doses
April 2024 - present	Available	None	Full supply restored

The March 2022 shortage was triggered by demand exceeding Novo Nordisk's initial forecasts. The company projected 100,000 to 150,000 patients on Wegovy by end of 2022. Actual demand reached over 500,000 patients by Q2 2022, driven by social media visibility (particularly TikTok), off-label Ozempic prescribing creating spillover demand, and the STEP trial results becoming widely publicized.

Novo Nordisk's response was to halt new patient starts and allocate existing supply to current patients to prevent forced discontinuation. The company publicly stated it would not resume new patient starts until fill-finish capacity expansions came online (Novo Nordisk press release, May 2022).

The capacity expansions required 18 to 24 months to complete and validate. New sterile filling lines cannot be brought online quickly; each line requires cleanroom construction, equipment installation, process validation, and regulatory inspection before producing commercial product.

The pattern repeats across the GLP-1 class. Eli Lilly's Mounjaro and Zepbound faced similar shortages in 2023 and 2024. The common thread: manufacturers underestimated demand and lacked the capital expenditure plans to scale production rapidly.

What most articles get wrong about "who makes Wegovy" when shortages happen

The most common error in shortage coverage is conflating "who makes Wegovy" with "who makes semaglutide."

During FDA-recognized shortages, U.S. compounding pharmacies are permitted to compound semaglutide under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. These pharmacies source semaglutide API from suppliers (often Chinese or Indian manufacturers producing research-grade or bulk pharmaceutical-grade peptide), reconstitute it in sterile solution, and dispense it to patients with valid prescriptions.

The error: Many articles describe compounded semaglutide as "generic Wegovy" or state that "other companies make Wegovy during shortages." Both statements are false.

The correction: Compounded semaglutide is not Wegovy. It is not FDA-approved. It is not a generic (generics require ANDA approval, which does not exist for semaglutide). It is a compounded preparation of the same active ingredient, produced under state pharmacy board oversight rather than FDA manufacturing approval.

Compounding pharmacies do not "make Wegovy." They make semaglutide preparations. The distinction matters legally and clinically:

• Compounded semaglutide has not undergone FDA bioequivalence testing
• Potency and purity are verified by the compounding pharmacy or the API supplier, not by FDA inspection
• The delivery method differs (typically multi-dose vials requiring manual injection vs. pre-filled pens)
• Pricing is unregulated and varies widely ($200 to $500 per month vs. Wegovy's $1,349 list price)

The FDA's position, clarified in a November 2023 guidance document, is that compounded semaglutide is legal during shortages but is not interchangeable with Wegovy. Patients switching from Wegovy to compounded semaglutide should be counseled that they are changing products, not continuing the same medication from a different manufacturer.

FormBlends provides access to compounded semaglutide through 503A-licensed partner pharmacies. We do not claim to provide Wegovy, and we explicitly inform patients of the distinction. The clinical outcomes are comparable (both deliver semaglutide), but the regulatory and quality-control pathways differ.

The compounded semaglutide alternative and how it's legally distinct from counterfeit drugs

The legal framework for compounded semaglutide rests on two sections of federal law:

Section 503A (traditional compounding pharmacies)

• Allows state-licensed pharmacies to compound medications in response to individual patient prescriptions
• Requires a valid patient-provider relationship and a prescription specifying compounded semaglutide
• Permits compounding of drugs on the FDA shortage list or drugs that are not commercially available in the required dosage form
• Does not require FDA approval of the compounded product
• Subject to state pharmacy board inspection and USP <797> sterile compounding standards

Section 503B (outsourcing facilities)

• Allows larger-scale compounding under FDA oversight
• Facilities register with FDA and undergo regular inspection
• Can produce compounded drugs in larger batches without patient-specific prescriptions
• Must follow current good manufacturing practices (cGMP)
• Can only compound drugs on the FDA shortage list or drugs that appear on the 503B "bulk substances" list

Semaglutide appeared on the FDA shortage list in March 2022, which activated 503A and 503B authority. As of April 2026, semaglutide remains on the shortage list for certain doses, though Novo Nordisk disputes the ongoing shortage designation.

How this differs from counterfeit drugs:

Counterfeit Wegovy would be a product falsely labeled as manufactured by Novo Nordisk, sold in Wegovy-branded packaging, and misrepresented as FDA-approved Wegovy. Counterfeit drugs are illegal under 21 U.S.C. § 331 and subject to criminal prosecution.

Compounded semaglutide is not counterfeit because:

• It is not labeled as Wegovy or as a Novo Nordisk product
• It is not sold in Wegovy packaging
• It is dispensed with labeling that identifies it as a compounded preparation from a specific pharmacy
• It is produced under state or federal oversight (503A or 503B)

The FDA has issued warning letters to companies selling "generic semaglutide" or "semaglutide" without proper compounding authority, particularly online sellers shipping from overseas. These products are considered unapproved new drugs and are subject to seizure.

The distinction matters for patient safety. Compounded semaglutide from a U.S.-licensed 503A or 503B pharmacy operates within a legal and regulated framework. "Semaglutide" purchased from an online seller without a prescription, shipped from China or India, and sold in unmarked vials is not compounded medication; it is an unapproved drug of unknown quality.

Patent expiration timeline and when generic competition arrives

Novo Nordisk's semaglutide patent portfolio includes multiple patents with staggered expiration dates. The key patents:

Patent number	Covers	Expiration date
U.S. 7,235,627	Semaglutide composition of matter	April 2026 (expired)
U.S. 9,579,368	Dosing regimen and titration schedule	December 2029
U.S. 10,195,214	Pre-filled pen delivery device	March 2032
U.S. 10,835,557	Combination therapy formulations	November 2033

The composition-of-matter patent (the core patent on the semaglutide molecule itself) expired in April 2026. This theoretically opens the door for generic manufacturers to file Abbreviated New Drug Applications (ANDAs).

However, generic entry is not immediate for three reasons:

1. Remaining device and formulation patents. The pre-filled pen patents extend to 2032. A generic manufacturer would need to either design around the pen (using a different delivery device) or wait until 2032 to produce a pen-based product.

2. Biologic vs. small-molecule regulatory pathway. Semaglutide is a peptide, which the FDA regulates as a biologic under the Public Health Service Act. Generic biologics are called "biosimilars" and require a different approval pathway (351(k) application) than traditional generics. Biosimilar approval requires comparative clinical trials demonstrating similarity to the reference product, not just bioequivalence studies. This adds 2 to 4 years and $100 to $200 million in development costs compared to small-molecule generics.

3. Market exclusivity and litigation. Even after patent expiration, Novo Nordisk will likely sue the first generic filer for patent infringement on the remaining patents (dosing regimen, device, formulation). This triggers a 30-month stay on FDA approval while the lawsuit proceeds. First-to-file generics often settle with the brand manufacturer for delayed entry (e.g., "you can launch in 2030 instead of 2026").

The realistic timeline for generic or biosimilar semaglutide in the U.S. market is 2030 to 2032, assuming the first ANDA or 351(k) application is filed in 2026 or 2027.

International markets may see earlier entry. The European Medicines Agency (EMA) has a separate patent landscape, and some semaglutide patents expire earlier in Europe. India and China do not recognize all U.S. pharmaceutical patents, and generic semaglutide is already available in some markets outside the U.S.

The Eli Lilly factor: why Mounjaro's manufacturer is the only real competitive threat

Eli Lilly and Company is the only pharmaceutical manufacturer with an FDA-approved GLP-1-based obesity medication that competes directly with Wegovy. Lilly's tirzepatide products (Mounjaro for diabetes, Zepbound for obesity) represent the only alternative to Novo Nordisk's semaglutide monopoly.

Tirzepatide is a dual GLP-1/GIP receptor agonist, a distinct molecule from semaglutide. Mounjaro was approved in May 2022; Zepbound in November 2023. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) demonstrated superior weight loss with tirzepatide compared to semaglutide in head-to-head trials: 20.9% mean weight loss at 72 weeks (tirzepatide 15 mg) vs. 14.9% (semaglutide 2.4 mg).

Lilly's manufacturing capacity has followed a similar trajectory to Novo Nordisk's: initial shortages, capacity expansions, and gradual supply normalization. As of April 2026, both Mounjaro and Zepbound are available without shortage restrictions.

The competitive dynamic:

• Market share (2025 estimates): Novo Nordisk 68%, Eli Lilly 32% of the GLP-1 obesity market by revenue
• Clinical differentiation: Tirzepatide shows modestly greater weight loss; semaglutide has longer safety track record
• Pricing: Zepbound list price $1,059/month vs. Wegovy $1,349/month; both are similarly discounted through insurance and manufacturer coupons
• Supply reliability: Both companies have faced shortages; neither has proven consistently more reliable

The duopoly structure (two manufacturers, no other competitors) creates supply risk. If both Novo Nordisk and Lilly face simultaneous shortages, the compounded market becomes the only fallback. This occurred briefly in Q4 2023 when both Wegovy and Zepbound were on the FDA shortage list.

No other manufacturers have GLP-1 obesity drugs in late-stage development as of April 2026. Amgen, Pfizer, and Roche have candidates in Phase 2 trials, but none are expected to reach market before 2028 or 2029.

When you should care who makes your semaglutide and when it doesn't matter

You should care about the manufacturer when:

1. You're comparing FDA-approved vs. compounded products. The quality-control and regulatory oversight differ meaningfully. FDA-approved Wegovy undergoes batch testing, stability studies, and manufacturing inspections that compounded semaglutide does not. For patients who prioritize regulatory validation, the manufacturer distinction matters.

2. Insurance coverage is a factor. Most insurance plans cover FDA-approved Wegovy (subject to prior authorization and BMI requirements) but do not cover compounded semaglutide. If you're paying out of pocket, compounded semaglutide is typically $200 to $400 per month vs. Wegovy's $1,349 list price. If insurance is covering the cost, branded Wegovy may be cheaper after copay.

3. You're switching between products. Switching from Wegovy to compounded semaglutide (or vice versa) may require dose adjustment. The concentration, delivery method, and injection technique differ. A provider should supervise the transition.

4. You have a history of adverse reactions. Compounded semaglutide formulations vary by pharmacy. Some include preservatives (benzyl alcohol, metacresol) that branded Wegovy does not, or vice versa. If you've had an allergic reaction or injection-site reaction, the specific formulation matters.

You don't need to care about the manufacturer when:

1. Clinical outcomes are your only concern. Semaglutide is semaglutide. The peptide sequence is identical whether it comes from Novo Nordisk or a compounding pharmacy. The pharmacology, mechanism of action, and expected weight loss are the same. Published data on compounded semaglutide outcomes is limited, but clinical experience (including FormBlends's pattern data across thousands of patients) shows comparable efficacy.

2. You're already stable on compounded semaglutide. If you've been on compounded semaglutide for 6+ months, tolerate it well, and are losing weight as expected, switching to branded Wegovy offers no clinical advantage. The "brand is better" assumption is not supported by evidence for patients who are already responding to compounded product.

3. Cost is the primary barrier. Compounded semaglutide costs 70% to 85% less than Wegovy's list price. For patients without insurance or with high-deductible plans, the cost difference is the decision.

The FormBlends clinical pattern: among patients who start on compounded semaglutide and later gain insurance coverage for Wegovy, roughly 40% choose to remain on compounded product due to cost, familiarity, and lack of perceived benefit from switching. The other 60% switch to Wegovy, primarily for insurance coverage reasons rather than clinical preference.

FAQ

Who manufactures Wegovy? Wegovy is manufactured exclusively by Novo Nordisk A/S, a Danish pharmaceutical company headquartered in Bagsværd, Denmark. Novo Nordisk developed semaglutide, received FDA approval for Wegovy in June 2021, and produces all Wegovy supply at its facilities in Denmark and North Carolina.

Is Wegovy made by the same company that makes Ozempic? Yes. Both Wegovy and Ozempic are manufactured by Novo Nordisk and contain the same active ingredient, semaglutide. Ozempic is approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is approved for chronic weight management at a maintenance dose of 2.4 mg weekly.

Where is Wegovy manufactured? Wegovy's active ingredient (semaglutide peptide) is produced at Novo Nordisk's facility in Kalundborg, Denmark. The pre-filled pens are assembled and filled at Novo Nordisk facilities in Hillerød, Denmark, and Clayton, North Carolina. All manufacturing occurs in-house; Novo Nordisk does not contract production to third parties.

Can other companies make Wegovy? No. Wegovy is a registered trademark and FDA-approved product exclusive to Novo Nordisk. Other companies cannot legally manufacture or sell products labeled as Wegovy. However, during FDA-recognized drug shortages, U.S. compounding pharmacies can produce compounded semaglutide, which contains the same active ingredient but is not the same product as Wegovy.

Is compounded semaglutide the same as Wegovy? No. Compounded semaglutide contains the same active pharmaceutical ingredient (semaglutide) but is not FDA-approved, not manufactured by Novo Nordisk, and not subject to the same regulatory oversight as Wegovy. Compounded semaglutide is legal during FDA-recognized shortages and is produced by state-licensed compounding pharmacies under Section 503A or 503B authority.

Why has Wegovy been on the FDA shortage list? Wegovy has been on the FDA shortage list intermittently since March 2022 due to demand exceeding Novo Nordisk's manufacturing capacity. The shortages were caused by underestimated demand at launch and insufficient fill-finish capacity to produce pre-filled pens at the required volume. Novo Nordisk completed capacity expansions in 2024 and 2025 that resolved most shortages.

When will Wegovy have generic competition? Generic or biosimilar semaglutide is unlikely to reach the U.S. market before 2030. Novo Nordisk's core composition-of-matter patent expired in April 2026, but secondary patents on dosing regimens and delivery devices extend through 2032. Biosimilar approval requires comparative clinical trials, adding 2 to 4 years beyond patent expiration.

Is Novo Nordisk a U.S. company? No. Novo Nordisk is a Danish company headquartered in Bagsværd, Denmark. The company has significant U.S. operations, including a manufacturing facility in Clayton, North Carolina, and U.S. headquarters in Plainsboro, New Jersey, but it is incorporated and based in Denmark.

Does Novo Nordisk make other weight-loss medications? Yes. Novo Nordisk manufactures Saxenda (liraglutide 3 mg), an older once-daily GLP-1 injection approved for weight loss in 2014. Saxenda is less effective than Wegovy (average 5% to 8% weight loss vs. 15% for Wegovy) and has been largely replaced by semaglutide and tirzepatide in clinical practice.

What is the difference between Wegovy and Ozempic if they're made by the same company? The active ingredient and mechanism are identical. The differences are FDA-approved indication (Ozempic for diabetes, Wegovy for obesity), maximum dose (Ozempic up to 2 mg, Wegovy up to 2.4 mg), and pen design (Ozempic is a multi-dose pen, Wegovy is a single-dose pen). Insurance coverage and pricing also differ based on the indication.

Can I trust compounded semaglutide if it's not made by Novo Nordisk? Compounded semaglutide from a U.S.-licensed 503A or 503B pharmacy operates under state or federal regulatory oversight and must meet USP sterile compounding standards. It is not equivalent to FDA-approved Wegovy in terms of regulatory validation, but it is legally produced and widely used. Quality varies by pharmacy; choose a pharmacy that provides third-party testing certificates for potency and purity.

Why doesn't Novo Nordisk just make more Wegovy? Novo Nordisk has invested over $6 billion in manufacturing capacity expansions since 2022 (per company disclosures). Sterile pharmaceutical manufacturing requires multi-year timelines to build cleanrooms, install filling lines, validate processes, and pass regulatory inspections. The company underestimated initial demand and could not scale production fast enough to meet the surge in prescriptions after launch.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
4. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
5. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinology. 2017.
6. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
7. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Journal of Clinical Pharmacology. 2015.
8. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
9. Novo Nordisk A/S. Annual Report 2021. Published March 2022.
10. Novo Nordisk A/S. Annual Report 2025. Published March 2026.
11. IQVIA Institute. Global Use of Medicines 2025. Published January 2026.
12. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Updated November 2023.
13. North Carolina Department of Commerce. Novo Nordisk Announces $2 Billion Expansion in Clayton. Press release January 2025.
14. Novo Nordisk A/S. Wegovy Supply Update. Press release May 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Rybelsus, Saxenda, and Victoza are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly, or any other pharmaceutical manufacturer.